|
Childhood Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Glioblastoma Multiforme
|
|
0.020 |
GeneticVariation
|
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Adult Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
It also suggests that RAL GTPase inhibition will be an important treatment strategy for tumors harboring RAS glycine to cysteine (G12C) or glycien to valine (G12V) mutations, which are commonly found in NSCLC and pancreatic cancer.
|
25557115 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation.
|
22247021 |
2012 |
|
Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
|
Glioblastoma Multiforme
|
|
0.020 |
GeneticVariation
|
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
|
Adult Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
|
Childhood Glioblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
|
Osteosarcoma of bone
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Methods:</b> Osteosarcoma cancer cell line MG-63 was transfected with Ras gene with G12V and Y40C site mutation.
|
31126199 |
2019 |
|
Osteosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Methods:</b> Osteosarcoma cancer cell line MG-63 was transfected with Ras gene with G12V and Y40C site mutation.
|
31126199 |
2019 |
|
Childhood Osteosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Methods:</b> Osteosarcoma cancer cell line MG-63 was transfected with Ras gene with G12V and Y40C site mutation.
|
31126199 |
2019 |
|
Glioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Mammary Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Application of these signatures to breast tumor gene expression data identified two novel discrete phenotypes characterized by concordant, aberrant activation of either the HER2, IGF1R, and AKT pathways ("the survival phenotype") or the EGFR, KRAS (G12V), RAF1, and BAD pathways ("the growth phenotype").
|
28446242 |
2017 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have developed a Drosophila lung cancer model by targeting Ras1(G12V)--alone or in combination with PTEN knockdown--to the Drosophila tracheal system.
|
26832408 |
2016 |
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have developed a Drosophila lung cancer model by targeting Ras1(G12V)--alone or in combination with PTEN knockdown--to the Drosophila tracheal system.
|
26832408 |
2016 |
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have developed a Drosophila lung cancer model by targeting Ras1(G12V)--alone or in combination with PTEN knockdown--to the Drosophila tracheal system.
|
26832408 |
2016 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
When expressed under the control of the krt5 gene promoter, KRAS(G12V) induced bra</span>in tumors in ventricular zones (VZ) at low frequency.
|
25644510 |
2015 |
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
It also suggests that RAL GTPase inhibition will be an important treatment strategy for tumors harboring RAS glycine to cysteine (G12C) or glycien to valine (G12V) mutations, which are commonly found in NSCLC and pancreatic cancer.
|
25557115 |
2015 |
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We demonstrated that transient transgenic expression of KRAS(G12V) in putative neural stem and/or progenitor cells induced brain tumorigenesis.
|
25644510 |
2015 |
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
It also suggests that RAL GTPase inhibition will be an important treatment strategy for tumors harboring RAS glycine to cysteine (G12C) or glycien to valine (G12V) mutations, which are commonly found in NSCLC and pancreatic cancer.
|
25557115 |
2015 |
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients whose tumors had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose tumors had other mutant KRas proteins or wild-type KRas (P = .046, median survival = 1.84 months) compared with all other mutant KRas (median survival = 3.35 months) or wild-type KRas (median survival = 1.95 months).
|
22247021 |
2012 |